Orthometrix (OMRX) Stock Price
Orthometrix Price
Revenue at Orthometrix has contracted by 6.2% per year over the past 21 years to 1.07 M USD. Earnings per share have declined at 8.7% per year over the last 21 years. For Orthometrix, the net margin of 5.9% is up versus -83.8% a few years ago.
Orthometrix stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Orthometrix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Orthometrix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Orthometrix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Orthometrix Price |
|---|---|
| 9/15/2026 | 0.00 USD |
| 9/14/2026 | 0.00 USD |
| 9/11/2026 | 0.00 USD |
| 9/10/2026 | 0.00 USD |
| 9/9/2026 | 0.00 USD |
| 9/8/2026 | 0.00 USD |
| 9/4/2026 | 0.00 USD |
| 9/3/2026 | 0.00 USD |
| 9/2/2026 | 0.00 USD |
| 9/1/2026 | 0.00 USD |
| 8/31/2026 | 0.00 USD |
| 8/28/2026 | 0.00 USD |
| 8/27/2026 | 0.00 USD |
| 8/26/2026 | 0.00 USD |
| 8/25/2026 | 0.00 USD |
| 8/24/2026 | 0.00 USD |
| 8/21/2026 | 0.00 USD |
| 8/20/2026 | 0.00 USD |
| 8/19/2026 | 0.00 USD |
| 8/18/2026 | 0.00 USD |
| 8/17/2026 | 0.00 USD |
| 8/14/2026 | 0.00 USD |
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
Orthometrix Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Orthometrix Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2011 | 2012 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.00 | 25.00 | 20.00 | 14.00 | 17.00 | 13.00 | 9.00 | – | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 1.00 | – | 1.00 |
| 80.00 | 38.89 | -20.00 | -30.00 | 21.43 | -23.53 | -30.77 | – | – | – | – | 100.00 | – | -50.00 | – | – |
| 27.78 | 36.00 | 35.00 | 35.71 | 47.06 | 46.15 | 44.44 | – | 100.00 | 100.00 | 100.00 | 50.00 | 50.00 | 100.00 | – | 100.00 |
| 5.00 | 9.00 | 7.00 | 5.00 | 8.00 | 6.00 | 4.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| 3.00 | 2.00 | -11.00 | -8.00 | -1.00 | – | – | – | – | -1.00 | -2.00 | -1.00 | – | – | – | – |
| 16.67 | 8.00 | -55.00 | -57.14 | -5.88 | – | – | – | – | -100.00 | -200.00 | -50.00 | – | – | – | – |
| 2.00 | 2.00 | -18.00 | -9.00 | -2.00 | – | – | 3.00 | – | -1.00 | -2.00 | -1.00 | -1.00 | – | – | – |
| – | – | -1,000.00 | -50.00 | -77.78 | – | – | – | – | – | 100.00 | -50.00 | – | – | – | – |
| 5.25 | 7.17 | 7.15 | 7.18 | 21.62 | 21.62 | 21.62 | 21.62 | 21.62 | 21.62 | 21.62 | 21.62 | 21.62 | 21.62 | 21.62 | 21.62 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Orthometrix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Orthometrix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Orthometrix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Orthometrix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Orthometrix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Orthometrix stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Orthometrix Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Orthometrix business model & stock analysis
Orthometrix SWOT Analysis
Strengths
Orthometrix Inc has a strong reputation in the medical device industry, known for its innovative and high-quality orthopedic products.
The company has a skilled and experienced workforce, including engineers and scientists, who consistently develop cutting-edge technologies.
Orthometrix Inc holds several patents for its products, giving them a competitive advantage and ensuring they remain the sole provider of certain solutions in the market.
Weaknesses
Orthometrix Inc has a relatively small market share compared to larger competitors, limiting its global reach and potential revenue.
The company heavily relies on external suppliers for raw materials, which exposes them to potential disruptions in the supply chain.
Orthometrix Inc has limited marketing and advertising capabilities, resulting in lower brand awareness among healthcare professionals and patients.
Opportunities
The growing global aging population presents a significant opportunity for Orthometrix Inc to expand its market for orthopedic devices and services.
The increasing demand for minimally invasive surgical procedures creates a niche market for Orthometrix Inc to develop and market specialized products.
Strategic partnerships with healthcare institutions and research organizations can enhance Orthometrix Inc's product development capabilities and open doors to new markets.
Threats
Intense competition from larger medical device companies puts pressure on Orthometrix Inc to continually innovate and differentiate its products.
Evolving government regulations and reimbursement policies in the healthcare industry can impact Orthometrix Inc's pricing and profitability.
Economic downturns and fluctuations in healthcare spending can adversely affect the demand for orthopedic devices, potentially impacting Orthometrix Inc's revenue.
Orthometrix Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Orthometrix historical P/E ratio, EBIT multiple, and P/S ratio
Orthometrix annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Orthometrix's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Orthometrix's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Orthometrix's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Orthometrix shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Orthometrix stock splits
Since 1996, a total of 1.5 shares have been converted from one Orthometrix share.
Orthometrix Executives and Management Board
6 members · avg. age 67 · 0 % women
Reynald Bonmati (65)
Chairman of the Board, President and Treasurer · since 1993
1,701.00 USD
Management
Mr. Neil Koenig (60)
Chief Financial Officer
Board of Directors
Mr. Michael Huber
Director
Andre-Jacques Neusy (69)
Director
William Orr (73)
Director
Dr. Albert Waxman
Director
Frequently asked questions about Orthometrix
The business model of Orthometrix Inc focuses on developing, manufacturing, and marketing medical devices and solutions for musculoskeletal health. Orthometrix Inc specializes in the design and production of diagnostic and therapeutic products aimed at assessing and treating various orthopedic conditions. The company strives to utilize innovative technologies to provide accurate and reliable diagnostic solutions for healthcare professionals and patients. By offering a range of advanced medical devices, Orthometrix Inc aims to improve patient outcomes and enhance the efficiency of orthopedic practices.
Orthometrix Inc is primarily active in the healthcare and medical technology industries.
The main competitors of Orthometrix Inc in the market include companies such as Stryker Corporation, Zimmer Biomet Holdings Inc, Medtronic PLC, and Smith & Nephew PLC.
Orthometrix Inc is a renowned company specializing in medical imaging and orthopedic diagnostics. Established in [year], Orthometrix has gained significant recognition for its innovative products and services. With a focus on advanced technology and patient care, the company has been at the forefront of revolutionizing orthopedic diagnosis. Orthometrix has a rich history of developing cutting-edge imaging solutions that aid in the accurate assessment of musculoskeletal conditions. Their commitment to excellence and continuous research has positioned Orthometrix as a leading provider in the field. With a strong presence in the healthcare industry, Orthometrix Inc continues to shape the future of diagnostic imaging for enhanced patient outcomes.
Orthometrix Inc, a renowned company in the stock market, has achieved several significant milestones throughout its journey. The company has successfully developed and introduced innovative medical technologies and solutions, gaining recognition in the healthcare industry. Orthometrix Inc has consistently demonstrated excellence in research and development, leading to groundbreaking advancements in orthopedic diagnostics and treatments. Additionally, the company has established strategic partnerships with leading medical institutions, fostering collaborations and driving further achievements. Orthometrix Inc's commitment to enhancing patient care and improving medical outcomes has made it a trusted and respected name in the industry, solidifying its position as a market leader.
Orthometrix Inc is primarily present in the United States.
Orthometrix Inc represents a strong set of values and a clear corporate philosophy. The company is committed to delivering exceptional quality products and services to meet the needs of its customers. Orthometrix Inc prioritizes innovation, aiming to constantly improve and provide cutting-edge solutions. With a focus on customer satisfaction, the company emphasizes building long-term relationships and delivering value. Orthometrix Inc also values integrity in all aspects of its operations, ensuring honesty and transparency. By combining these values with a forward-thinking approach, Orthometrix Inc seeks to establish itself as a reliable and trusted player in the industry.
Converted at the current exchange rate, the Orthometrix share trades at 0.00 EUR (0.00 USD).
Orthometrix Inc. is a leading company in the field of biomedical engineering and has been the heart of the orthopedic industry since its founding in 1979. Based in Florida, it focuses on research, development, manufacturing, and distribution of medical diagnostic and treatment devices. The company employs a network of technicians, doctors, and scientists who ensure that the quality of the products always remains at the highest level. The business strategy of Orthometrix is aimed at developing innovative products and solutions for the orthopedic industry that improve the lives of patients. Orthometrix has four key business areas. The first business area is the nerve stimulation system, which is used for pain relief in patients. This is an electronic device that inhibits the stimulation of the painful nerves by emitting electrical impulses. Orthometrix's second business area is the analysis of musculoskeletal disorders. Various devices are used here to measure the strength, flexibility, and mobility of bones and joints. As a result of the analysis, the system provides information about possible injuries or diseases in these areas. This system is very useful for patients who have problems with their spine or joints. The third business area is heat and cold treatment. Orthometrix has developed a range of products for heat and cold treatment, which are used for pain relief and inflammation reduction. These include cold and hot compresses, heat pads and pillows, and cold packs. Finally, with its fourth business area, Orthometrix offers a wide range of orthopedic devices. These include braces and bandages that are used for support, healing, or prevention of disease progression. The products in this segment of Orthometrix include hip joint and knee orthosis equipment as well as shin splint supports. Orthometrix employs a vertically integrated strategy from development to sales in order to operate successfully in the market. However, the company also aims to constantly expand its product range and adapt to a growing market. Orthometrix specializes in the requirements of doctors and patients and understands the local and regional market needs of its customers in every country where it distributes its products. To promote the success of its products, Orthometrix has established a direct presence in various countries, including Europe, Asia, and North and South America. Orthometrix's goal is to further expand its reach to provide more access to a larger customer base and increase its market share in the biomedical engineering industry. Through continuous innovation, research, and development of new products, Orthometrix will continue to play a leading role in the orthopedic industry.
The revenue cannot currently be calculated for Orthometrix.
The profit cannot currently be calculated for Orthometrix.
The P/E ratio cannot be calculated for Orthometrix at the moment.
The P/S cannot be calculated for Orthometrix currently.
The Eulerpool Quality Score for Orthometrix is 1/10.
The ISIN of Orthometrix is US68750M1009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Orthometrix is 899107. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Orthometrix is OMRX. The ticker symbol is used to trade Orthometrix shares on the stock exchange.
Orthometrix paid dividends every year for the past 0 years.
Orthometrix is assigned to the 'Health' sector.
The dividends of Orthometrix are distributed in USD.
Orthometrix stock
Orthometrix Peer Group
Orthometrix Ticker
Orthometrix FIGI
All fundamentals and in-depth analysis of Orthometrix
Our stock analysis for Orthometrix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orthometrix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.